Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia

Urol Int. 2011;86(3):284-9. doi: 10.1159/000322645. Epub 2011 Feb 8.


Introduction: The study aimed to evaluate the long-term efficacy of treatment with extract of Serenoa repens (Prostamol Uno) in patients with lower urinary tract symptoms (LUTS) induced by benign prostatic hyperplasia (BPH).

Patients and methods: We studied 120 patients with mild or moderate LUTS induced by BPH, maximal urinary flow (Q(max)) <15 ml with a voided volume ≥150 ml, prostate-specific antigen <4 ng/ml, and residual urinary volume <150 ml, treated daily for 24 months with one capsule of 320 mg ethanolic extract of Serenoa repens.

Results: Statistically significant improvements in the International Prostate Symptom Score (5.5 points), quality of life (QoL; 1.8 points), Q(max) (5.6 ml/s), International Index of Erectile Function (IIEF; 6.4 points) and reduction in residual urinary volume were observed during the study period. The mean prostate volume at 24 months was 36 ml, compared to 39.8 ml at baseline.

Conclusions: Long-term treatment with 320 mg ethanolic extract of Serenoa repens proved to be efficient in reducing urinary obstruction, improving symptomatology and QoL of BPH patients. It also had a positive effect on sexual function, demonstrated by the statistically significant increase in the IIEF.

MeSH terms

  • Ethanol / pharmacology
  • Humans
  • Male
  • Models, Statistical
  • Penile Erection
  • Phytotherapy / methods
  • Plant Extracts / pharmacology*
  • Prostate
  • Prostatic Hyperplasia / drug therapy*
  • Quality of Life
  • Serenoa / metabolism*
  • Time Factors
  • Treatment Outcome
  • Urinary Tract / drug effects
  • Urination


  • Plant Extracts
  • Ethanol